Showing results (231-240 of 538) with videos related to
Sort By:
Pageof 54
Joint Bone Spine|April 12, 2014
Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practiceAline Frazier-Mironer, Maxime Dougados, Xavier Mariette, et al.Seminars in Arthritis and Rheumatism|February 10, 2024
Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working groupYann Nguyen, Maxime Beydon, Nathan Foulquier, et al.The Journal of Rheumatology|April 1, 2025
A Systematic Review of Clinical Trial Designs and Outcome Measures in Sjögren Disease Randomized Controlled TrialsMaxime Beydon, Yann Nguyen, Rachael Gordon, et al.Joint Bone Spine|December 10, 2016
Patient-perceived flares in rheumatoid arthritis: A sub-analysis of the STRASS treatment tapering strategy trialAgnès Portier, Laure Gossec, Florence Tubach, et al.Frontiers in Immunology|April 23, 2020
A Machine Learning Approach for High-Dimensional Time-to-Event Prediction With Application to Immunogenicity of Biotherapies in the ABIRISK CohortJulianne Duhazé, Signe Hässler, Delphine Bachelet, et al.Annals of the Rheumatic Diseases|March 3, 2007
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trialGerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, et al.Journal of Autoimmunity|January 14, 2014
Outcome measures for primary Sjögren's syndrome: a comprehensive reviewRaphaèle Seror, Elke Theander, Hendrika Bootsma, et al.Bulletin Du Cancer|June 1, 2024
Post-transcriptional gene regulation: From mechanisms to RNA chemistry and therapeuticsClara Bonnet, Ana Luisa Dian, Tristan Espie-Caullet, et al.The New England Journal of Medicine|July 12, 2002
Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infectionOlivier Hermine, François Lefrère, Jean-Pierre Bronowicki, et al.Arthritis Research & Therapy|July 20, 2010
Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control studyMélanie Gilson, Laure Gossec, Xavier Mariette, et al.Pageof 54